Channelling of statin use towards low-risk population and patients with diabetes

Basic and Clinical Pharmacology and Toxicology

Volumn 113, Issue 3, 2013, Pages 173-178

  Rikala, Maria ^a   Huupponen, Risto ^a,b   Helin Salmivaara, Arja ^a,c   Korhonen, Maarit Jaana ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COMORBIDITY; DIABETES MELLITUS; DRUG USE; FEMALE; FINLAND; HUMAN; LOW RISK POPULATION; MALE; PRIORITY JOURNAL; RISK REDUCTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS;

EID: 84880703056     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12075     Document Type: Article

References (39)

1. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
2. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012;33:1635-701.
4. Current Care Guidelines. Dyslipidemias. Working group set up by the Finnish Medical Society Duodecim and Finnish Society of Internal Medicine. The Finnish Medical Society Duodecim, Finland, 2009. http://www.kaypahoito.fi/web/kh/suositukset/naytaartikkeli/ tunnus/hoi50025 (last accessed on 12 March 2013).
5. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
6. Blaha MJ, Nasir K, Blumenthal RS. Statin therapy for healthy men identified as "increased risk". JAMA 2012;307:1489-90.
7. Ebrahim S, Casas JP. Statins for all by the age of 50 years? Lancet 2012;380:545-7.
8. Redberg RF, Katz MH. Healthy men should not take statins. JAMA 2012;307:1491-2.
9. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius AJ, de Boer A. Time trends in lipid lowering drug use in the Netherlands. Has the backlog of candidates for treatment been eliminated?. Br J Clin Pharmacol 2002;53:379-85.
10. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005;60:543-51.
11. Ruokoniemi P, Helin-Salmivaara A, Klaukka T, Neuvonen PJ, Huupponen R. Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland. Br J Clin Pharmacol 2008;66:405-10.
12. Upmeier E, Korhonen MJ, Helin-Salmivaara A, Huupponen R. Statin use among older Finns stratified according to cardiovascular risk. Eur J Clin Pharmacol 2013;69:261-7.
13. Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy 2012;108:216-27.
14. Müller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J 2008;29:1316-26.
15. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94.
16. Finnish Medicines Agency, Social Insurance Institution. Finnish Statistics of Medicines 2010. Finnish Medicines Agency, Social Insurance Institution, Helsinki, 2011.
17. Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care 2010;48:761-6.
18. World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2011. World Health Organization Collaborating Centre for Drug Statistics Methodology, Oslo, 2010.
19. Lesén E, Sandström TZ, Carlsten A, Jönsson AK, Mårdby AC, Sundell KA. A comparison of two methods for estimating refill adherence to statins in Sweden: the RARE project. Pharmacoepidemiol Drug Saf 2011;20:1073-9.
20. Peltola M, Juntunen M, Häkkinen U, Rosenqvist G, Seppälä TT, Sund R. A methodological approach for register-based evaluation of cost and outcomes in health care. Ann Med 2011;43(Suppl 1):S4-13.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
22. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. ; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
23. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
24. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. ; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atovastatin Diabetes Study (CARDS). Lancet 2004;364:685-96.
25. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
26. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
27. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-13.
28. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
29. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;31:1CD004816.
30. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118:1294-303.
31. Mihos CG, Santana O. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med 2011;4:261-71.
32. Koskinen H, Martikainen JE, Maljanen T. Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005. Clin Ther 2009;31:1469-77.
33. Sihvo S, Wahlbeck K, McCallum A, Sevon T, Arffman M, Haukka J et al. Increase in the duration of antidepressant treatment from 1994 to 2003: a nationwide population-based study from Finland. Pharmacoepidemiol Drug Saf 2010;19:1186-93.
34. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-91.
35. Sheppard JP, Singh S, Fletcher K, McManus RJ, Mant J. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ 2012;12:345.
36. Hubbard RE, O'Mahony MS, Woodhouse KW. Medication prescribing in frail older people. Eur J Clin Pharmacol 2013;69:319-26.
37. Kiviniemi V, Peura P, Helin-Salmivaara A, Martikainen JE, Hartikainen J, Huupponen R et al. Suboptimal use of statins at treatment initiation. Eur J Clin Pharmacol 2011;67:971-3.
38. Korhonen MJ, Helin-Salmivaara A, Huupponen R. Dynamics of long-term statin therapy. Eur J Clin Pharmacol 2011;67:925-31.
39. Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007;167:847-52.